PRESSEMITTEILUNGEN

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information Heidelberg (euro adhoc) – Planegg/Munich (Germany), Princeton, NJ and Houston, TX, March 16, 2011 -Agennix AG (Frankfurt Stock Exchange: AGX) today announced the completion of patient enrollment in the talactoferrin FORTIS-M Phase III registration [...]

Continue reading

Agennix, Agx, Cell Lung Cancer, Clinical Investigators, Death Events, Double Blind Trial, Fortis, Frankfurt Stock Exchange, Information Heidelberg, Lung Cancer Patients, M Phase, Munich Germany, Non Small Cell Lung Cancer, Nsclc, Patient Enrollment, Planegg, Princeton Nj, Small Cell Lung Cancer, Supportive Care, Treatment Regimens

Orlando, Florida (ots/PRNewswire) – Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted [...]

Continue reading

American Society Of Clinical Oncology, Asco Meeting, Cell Lung Cancer, Docetaxel, Endpoint, Free Survival, Hazard Ratio, Investigational Drug, Length Of Time, Lung Cancer, Lung Cancer Patients, Non Small Cell Lung Cancer, Oncology, Orlando Florida, Phase Iii, Prnewswire, Significant Improvement, Small Cell Lung Cancer, Vandetanib

Basel, Switzerland (ots/PRNewswire) – – For ex-US Media Only – Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin(R) (bevacizumab) and Tarceva(R) (erlotinib) as combined first-line maintenance treatment had a [...]

Continue reading

Avastin, Basel Switzerland, Bevacizumab, Cell Lung Cancer, Erlotinib, Free Survival, Initial Chemotherapy, Initial Treatment, Line Maintenance, Lung Cancer Patients, Maintenance Therapy, Maintenance Treatment, Non Small Cell Lung Cancer, Nsclc, Prnewswire, Small Cell Lung Cancer, Study Saturn, Survival Time, Tarceva, Time Patients

Basel, Switzerland (ots/PRNewswire) – – New Phase III Study Will Evaluate if Tarceva is Superior to Traditional Chemotherapy in First Line Treatment of key Group of Patients Roche and the Spanish Lung Cancer Group (SLCG) today announced their collaboration on the first phase III trial to investigate Tarceva(R) (erlotinib) in lung cancer patients with genetic [...]

Continue reading

Asian Patients, Basel Switzerland, Cancer Group, Cell Lung Cancer, Chemotherapy Regimen, Dramatic Response, Egfr, Epidermal Growth Factor, Epidermal Growth Factor Receptor, Genetic Mutations, Growth Factor Receptor, Lung Cancer Patients, Non Small Cell Lung Cancer, Rafael Rosell, Small Cell Lung Cancer, Survival Benefits, Tarceva, Traditional Chemotherapy, Treatment Of Lung Cancer, Western Population